Roger Farah - CVS Health Independent Director
| CVS Stock | USD 64.48 0.62 0.97% |
Director
Mr. Roger N. Farah is Independent Director of the Company. He was a director at Aetna since 2007 and Chairman of the Board and a director of Tiffany Co. . He served as Executive Director of Tory Burch LLC from March 2017 to September 2017, having previously served as CoChief Executive Officer and Director from September 2014 to February 2017. He is former Executive Vice Chairman of Ralph Lauren Corporation having served in that position from November 2013 to May 2014, and previously served as President and Chief Operating Officer from April 2000 to October 2013, and Director from April 2000 to August 2014. Earlier, Mr. Farah served as Chairman of the Board of Venator Group, Inc. from December 1994 to April 2000, and as its Chief Executive Officer from December 1994 to August 1999. Mr. Farah served as President and Chief Operating Officer of R.H. Macy Co., Inc. from July 1994 to October 1994. From June 1991 to July 1994, he was Chairman and Chief Executive Officer of Federated Merchandising Services, the central buying and product development arm of Federated Department Stores, Inc. . From 1988 to 1991, Mr. Farah served as Chairman and Chief Executive Officer of RichsGoldsmiths Department Stores and previously as its President from 1987 to 1988. He held a number of positions of increasing responsibility at Saks Fifth Avenue, Inc. from 1975 to 1987 since 2018.
| Age | 72 |
| Tenure | 7 years |
| Address | One CVS Drive, Woonsocket, RI, United States, 02895 |
| Phone | 401 765 1500 |
| Web | https://www.cvshealth.com |
Roger Farah Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Farah against CVS Health stock is an integral part of due diligence when investing in CVS Health. Roger Farah insider activity provides valuable insight into whether CVS Health is net buyers or sellers over its current business cycle. Note, CVS Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell CVS Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Farah over six months ago Acquisition by Roger Farah of 4411 shares of CVS Health subject to Rule 16b-3 |
CVS Health Management Efficiency
The company has Return on Asset of 0.0199 % which means that on every $100 spent on assets, it made $0.0199 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0602 %, implying that it generated $0.0602 on every 100 dollars invested. CVS Health's management efficiency ratios could be used to measure how well CVS Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.12 in 2025, whereas Return On Tangible Assets are likely to drop 0.03 in 2025. At this time, CVS Health's Asset Turnover is comparatively stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Daniel Cooperman | Molina Healthcare | 70 | |
| Donna Zarcone | Cigna Corp | 63 | |
| Kimberly Ross | Cigna Corp | 56 | |
| Timothy Flynn | UnitedHealth Group Incorporated | 64 | |
| James OBrien | Humana Inc | 66 | |
| John Noseworthy | UnitedHealth Group Incorporated | 69 | |
| Tommy Thompson | Centene Corp | 78 | |
| Richard Gephardt | Centene Corp | 79 | |
| Garrey Carruthers | Molina Healthcare | 80 | |
| Eric Wiseman | Cigna Corp | 65 | |
| Robert Ditmore | Centene Corp | 86 | |
| Richard Zoretic | Molina Healthcare | 62 | |
| William Ballard | UnitedHealth Group Incorporated | 77 | |
| William McDonald | Humana Inc | 64 | |
| George Kurian | Cigna Corp | 54 | |
| Frank DAmelio | Humana Inc | 63 | |
| Marissa Peterson | Humana Inc | 58 | |
| David Feinberg | Humana Inc | 58 | |
| David Jones | Humana Inc | 71 | |
| Steven Orlando | Molina Healthcare | 69 | |
| Gail Wilensky | UnitedHealth Group Incorporated | 76 | |
Management Performance
| Return On Equity | 0.0602 | ||||
| Return On Asset | 0.0199 |
CVS Health Corp Leadership Team
Elected by the shareholders, the CVS Health's board of directors comprises two types of representatives: CVS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CVS. The board's role is to monitor CVS Health's management team and ensure that shareholders' interests are well served. CVS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CVS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Independent Director | ||
| Sreekanth MD, Executive Officer | ||
| David Dorman, Independent Chairman of the Board | ||
| Shawn Guertin, Chief Financial Officer, Executive Vice President | ||
| Mary Schapiro, Independent Director | ||
| FACEP MD, VP Officer | ||
| Fernando Aguirre, Independent Director | ||
| Laurence McGrath, Senior Relations | ||
| Laurie Havanec, Chief People Officer, Executive Vice President | ||
| Norman Greve, Chief Officer | ||
| C Brown, Independent Director | ||
| NancyAnn DeParle, Independent Director | ||
| David CEBS, Executive Caremark | ||
| Tilak Mandadi, Data, Digital | ||
| Thomas Cowhey, Executive CFO | ||
| JeanPierre Millon, Independent Director | ||
| Alecia DeCoudreaux, Independent Director | ||
| William Weldon, Independent Director | ||
| Larry McGrath, Sr Relations | ||
| Samrat Esq, Chief VP | ||
| Joshua Flum, Executive Vice President, Chief Strategy and Business Development Officer | ||
| Heidi Capozzi, Executive Officer | ||
| Troyen Brennan, Executive Vice President Chief Medical Officer | ||
| Prem Shah, Executive Vice President, Chief Pharmacy Officer and Co-President of Retail | ||
| Lisa Bisaccia, Chief Human Resource Officer, Executive Vice President | ||
| Karen Lynch, President, Chief Executive Officer, Director | ||
| Thomas Moriarty, Executive Vice President, General Counsel, Chief Policy and External Affairs Officer | ||
| Katerina Guerraz, Chief VP | ||
| Tony White, Independent Director | ||
| Anne Finucane, Independent Director | ||
| Vijay Patel, Senior CoFounder | ||
| James Clark, Senior Vice President - Controller, Chief Accounting Officer | ||
| Eva Boratto, Chief Financial Officer, Executive Vice President | ||
| David Falkowski, Executive Officer | ||
| Prem PharmD, Executive President | ||
| Jonathan Roberts, Chief Operating Officer, Executive Vice President | ||
| Gustavo Giraldo, Head Benefits | ||
| Daniel Finke, Executive Vice President and Presidentident - Health Care Benefits Segment | ||
| Larry Merlo, President, Chief Executive Officer, Director | ||
| Alan Lotvin, Executive Vice President and Presidentident - CVS Caremark | ||
| Neela Montgomery, Executive Vice President and President - CVS Pharmacy/Retail | ||
| Alan MD, Ex Services | ||
| Roger Farah, Independent Director | ||
| Sheryl Burke, Chief Responsibility | ||
| MPP MD, Senior President | ||
| Michelle Peluso, Executive Vice President, Chief Customer Officer and Co-President of Retail |
CVS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CVS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0602 | ||||
| Return On Asset | 0.0199 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 152.44 B | ||||
| Shares Outstanding | 1.26 B | ||||
| Shares Owned By Insiders | 0.35 % | ||||
| Shares Owned By Institutions | 84.97 % | ||||
| Number Of Shares Shorted | 21.35 M | ||||
| Price To Earning | 42.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CVS Stock Analysis
When running CVS Health's price analysis, check to measure CVS Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CVS Health is operating at the current time. Most of CVS Health's value examination focuses on studying past and present price action to predict the probability of CVS Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CVS Health's price. Additionally, you may evaluate how the addition of CVS Health to your portfolios can decrease your overall portfolio volatility.